0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose:

          Lynch syndrome (LS) is a hereditary condition with a high lifetime risk of colorectal and endometrial cancers. Exercise is a non-pharmacologic intervention to reduce cancer risk, though its impact on patients with LS has not been prospectively studied. Here, we evaluated the impact of a 12-month aerobic exercise cycling intervention in the biology of the immune system in LS carriers.

          Patients and Methods:

          To address this, we enrolled 21 patients with LS onto a non-randomized, sequential intervention assignation, clinical trial to assess the effect of a 12-month exercise program that included cycling classes 3 times weekly for 45 minutes versus usual care with a one-time exercise counseling session as control. We analyzed the effects of exercise on cardiorespiratory fitness, circulating, and colorectal-tissue biomarkers using metabolomics, gene expression by bulk mRNA sequencing, and spatial transcriptomics by NanoString GeoMx.

          Results:

          We observed a significant increase in oxygen consumption (VO 2peak) as a primary outcome of the exercise and a decrease in inflammatory markers (prostaglandin E) in colon and blood as the secondary outcomes in the exercise versus usual care group. Gene expression profiling and spatial transcriptomics on available colon biopsies revealed an increase in the colonic mucosa levels of natural killer and CD8 + T cells in the exercise group that were further confirmed by IHC studies.

          Conclusions:

          Together these data have important implications for cancer interception in LS, and document for the first-time biological effects of exercise in the immune system of a target organ in patients at-risk for cancer.

          Related collections

          Most cited references49

          • Record: found
          • Abstract: found
          • Article: not found

          Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

          The role of the adaptive immune response in controlling the growth and recurrence of human tumors has been controversial. We characterized the tumor-infiltrating immune cells in large cohorts of human colorectal cancers by gene expression profiling and in situ immunohistochemical staining. Collectively, the immunological data (the type, density, and location of immune cells within the tumor samples) were found to be a better predictor of patient survival than the histopathological methods currently used to stage colorectal cancer. The results were validated in two additional patient populations. These data support the hypothesis that the adaptive immune response influences the behavior of human tumors. In situ analysis of tumor-infiltrating immune cells may therefore be a valuable prognostic tool in the treatment of colorectal cancer and possibly other malignancies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

            Although tumor-infiltrating T cells have been documented in ovarian carcinoma, a clear association with clinical outcome has not been established. We performed immunohistochemical analysis of 186 frozen specimens from advanced-stage ovarian carcinomas to assess the distribution of tumor-infiltrating T cells and conducted outcome analyses. Molecular analyses were performed in some tumors by real-time polymerase chain reaction. CD3+ tumor-infiltrating T cells were detected within tumor-cell islets (intratumoral T cells) in 102 of the 186 tumors (54.8 percent); they were undetectable in 72 tumors (38.7 percent); the remaining 12 tumors (6.5 percent) could not be evaluated. There were significant differences in the distributions of progression-free survival and overall survival according to the presence or absence of intratumoral T cells (P<0.001 for both comparisons). The five-year overall survival rate was 38.0 percent among patients whose tumors contained T cells and 4.5 percent among patients whose tumors contained no T cells in islets. Significant differences in the distributions of progression-free survival and overall survival according to the presence or absence of intratumoral T cells (P<0.001 for both comparisons) were also seen among 74 patients with a complete clinical response after debulking and platinum-based chemotherapy: the five-year overall survival rate was 73.9 percent among patients whose tumors contained T cells and 11.9 percent among patients whose tumors contained no T cells in islets. The presence of intratumoral T cells independently correlated with delayed recurrence or delayed death in multivariate analysis and was associated with increased expression of interferon-gamma, interleukin-2, and lymphocyte-attracting chemokines within the tumor. The absence of intratumoral T cells was associated with increased levels of vascular endothelial growth factor. The presence of intratumoral T cells correlates with improved clinical outcome in advanced ovarian carcinoma. Copyright 2003 Massachusetts Medical Society
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6.

              1. Plasma interleukin (IL)-6 concentration is increased with exercise and it has been demonstrated that contracting muscles can produce IL-The question addressed in the present study was whether the IL-6 production by contracting skeletal muscle is of such a magnitude that it can account for the IL-6 accumulating in the blood. 2. This was studied in six healthy males, who performed one-legged dynamic knee extensor exercise for 5 h at 25 W, which represented 40% of peak power output (Wmax). Arterial-femoral venous (a-fv) differences over the exercising and the resting leg were obtained before and every hour during the exercise. Leg blood flow was measured in parallel by the ultrasound Doppler technique. IL-6 was measured by enzyme-linked immunosorbent assay (ELISA). 3. Arterial plasma concentrations for IL-6 increased 19-fold compared to rest. The a-fv difference for IL-6 over the exercising leg followed the same pattern as did the net IL-6 release. Over the resting leg, there was no significant a-fv difference or net IL-6 release. The work was produced by 2.5 kg of active muscle, which means that during the last 2 h of exercise, the median IL-6 production was 6.8 ng min-1 (kg active muscle)-1 (range, 3.96-9.69 ng min-1 kg-1). 4. The net IL-6 release from the muscle over the last 2 h of exercise was 17-fold higher than the elevation in arterial IL-6 concentration and at 5 h of exercise the net release during 1 min was half of the IL-6 content in the plasma. This indicates a very high turnover of IL-6 during muscular exercise. We suggest that IL-6 produced by skeletal contracting muscle contributes to the maintenance of glucose homeostasis during prolonged exercise.
                Bookmark

                Author and article information

                Journal
                Clin Cancer Res
                Clin Cancer Res
                Clinical Cancer Research
                American Association for Cancer Research
                1078-0432
                1557-3265
                01 November 2023
                27 September 2023
                : 29
                : 21
                : 4361-4372
                Affiliations
                [1 ]Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
                [2 ]Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
                [3 ]Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson, Houston, Texas.
                [4 ]Clinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, Houston, Texas.
                [5 ]Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
                [6 ]Department of Medicine, Harvard Medical School, Boston, Massachusetts.
                [7 ]Department of Behavioral Science, The University of Texas MD Anderson, Houston, Texas.
                [8 ]Department of Genomic Medicine, The University of Texas MD Anderson, Houston, Texas.
                [9 ]The Immunotherapy Platform, The University of Texas MD Anderson, Houston, Texas.
                [10 ]Department of Surgical Oncology, The University of Texas MD Anderson, Houston, Texas.
                [11 ]Department of Behavioral Science, The University of Texas MD Anderson, Houston, Texas.
                [12 ]Department of Immunology, The University of Texas MD Anderson, Houston, Texas.
                [13 ]Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson, Houston, Texas.
                [14 ]Department of Genitourinary Medical Oncology, The University of Texas MD Anderson, Houston, Texas.
                [15 ]Department of Cardiology, The University of Texas MD Anderson, Houston, Texas.
                Author notes
                [#]

                S.C. Gilchrist and E. Vilar contributed equally as co-directors of this article.

                [##]

                N. Deng and L. Reyes-Uribe contributed equally to this article.

                Trial Registration: ClinicalTrials.gov identifier: NCT03495674

                [* ] Corresponding Author: Eduardo Vilar, Clinical Cancer Prevention – Unit 1360, The University of Texas MD Anderson Cancer Center, PO Box 301439, Houston, TX 77230-1439. E-mail: EVilar@ 123456mdanderson.org

                Clin Cancer Res 2023;29:4361–72

                Author information
                https://orcid.org/0000-0002-9228-4519
                https://orcid.org/0000-0001-6091-6705
                https://orcid.org/0000-0001-5088-0198
                https://orcid.org/0009-0002-2947-0113
                https://orcid.org/0000-0001-9654-4958
                https://orcid.org/0000-0003-3067-0972
                https://orcid.org/0000-0001-9630-3046
                https://orcid.org/0000-0002-6276-1425
                https://orcid.org/0000-0002-9062-7338
                https://orcid.org/0000-0001-5981-7590
                https://orcid.org/0000-0003-0125-3109
                https://orcid.org/0000-0001-9093-7259
                https://orcid.org/0000-0002-6395-4499
                https://orcid.org/0000-0002-3911-6815
                https://orcid.org/0009-0006-1046-4863
                https://orcid.org/0000-0003-2130-3118
                https://orcid.org/0000-0001-7299-0646
                https://orcid.org/0000-0001-9847-8544
                https://orcid.org/0000-0003-3438-7576
                https://orcid.org/0000-0002-9915-0943
                https://orcid.org/0000-0001-8980-5697
                https://orcid.org/0000-0003-4658-055X
                https://orcid.org/0000-0002-7163-7151
                https://orcid.org/0000-0002-4210-1593
                https://orcid.org/0000-0001-9624-0292
                https://orcid.org/0000-0001-6404-3761
                Article
                CCR-23-0088
                10.1158/1078-0432.CCR-23-0088
                10618653
                37724990
                92ced82b-dd63-498f-9423-68f0dc672fdc
                ©2023 The Authors; Published by the American Association for Cancer Research

                This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

                History
                : 13 January 2023
                : 20 July 2023
                : 28 August 2023
                Page count
                Pages: 12
                Funding
                Funded by: National Cancer Institute (NCI), https://doi.org/10.13039/100000054;
                Award ID: CA016672
                Funded by: National Cancer Institute (NCI), https://doi.org/10.13039/100000054;
                Award ID: P50CA221707
                Categories
                Clinical Trials: Targeted Therapy

                Comments

                Comment on this article